LRRK2 antibody (AA 930-961)

Catalog No. ABIN3031610

Product Details anti-LRRK2 Antibody

Target: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Binding Specificity: AA 930-961

Reactivity: Human, Mouse

Host: Rabbit

Clonality: Polyclonal

Conjugate: This LRRK2 antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunofluorescence (IF)

Purification: Antigen affinity purified

Immunogen: A portion of amino acids 930-961 from the human protein was used as the immunogen for this PARK8 antibody.

Isotype: Ig Fraction

Application Details

Application Notes: Titration of the PARK8 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 1:1000,Immunofluorescence: 1:10-1:50

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the PARK8 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.

Target Details for LRRK2

Target: LRRK2 (Leucine-Rich Repeat Kinase 2 (LRRK2))

Alternative Name: PARK8 (LRRK2 Products)

Synonyms: LRRK2 antibody, AURA17 antibody, DARDARIN antibody, PARK8 antibody, RIPK7 antibody, ROCO2 antibody, 4921513O20Rik antibody, 9330188B09Rik antibody, AW561911 antibody, D630001M17Rik antibody, Gm927 antibody, cI-46 antibody, leucine-rich repeat kinase 2 antibody, leucine rich repeat kinase 2 antibody, lrrk2 antibody, LRRK2 antibody, Lrrk2 antibody

Background: Parkinson is the second most common neurodegenerative disease after Alzheimers. About 1 percent of people over the age of 65 and 3 percent of people over the age of 75 are affected by the disease. The mutation is the most common cause of Parkinson's disease identified to date. LRRK2/PARK8, a genetic mutation, was recently found linked to about 5 percent of inherited cases of Parkinson's disease. By high-resolution recombination mapping and candidate gene sequencing in 46 families, 6 disease-segregating mutations (5 missense and 1 putative splice site mutation). It may be central to the pathogenesis of several major neurodegenerative disorders associated with parkinsonism. PARK8 belongs to the ROCO protein family and includes a protein kinase domain of the MAPKKK class and several other major functional domains.

UniProt: Q5S007

Pathways: Regulation of G-Protein Coupled Receptor Protein Signaling, Skeletal Muscle Fiber Development